A designed fusion tag improves soluble expression of nanobody in E. coli Authors: Xingyu Wang, Ali Raza, Zhiqing Tao, Guan Wang, Xu Zhang, Maili Liu, Lichun He Published: 2026 ABSTRACT AbstractNanobodies are small, single-domain antibody fragments derived from camelid heavy-chain antibodies that offer high stability, strong binding affinity, and excellent potential for therapeutic and diagnostic applications. Producing aggregation-prone single-domain antibodies (nanobodies) recombinantly in Escherichia coli (E. coli) remains a significant biotechnological challenge, frequently leading to insoluble inclusion bodies and low functional yields. To overcome this, we designed fusion constructs of the tandem periplasmic chaperone Spheroplast Protein Y from E. coli (EcSpy) with aggregation-prone Taq and HER2-specific nanobodies, employing its native signal peptide to direct periplasmic export and its chaperone property to aid nanobody folding. This approach markedly enhanced soluble nanobody production, as evidenced by SDS-PAGE analysis during purification. After multi-step purification, approximately 10.0 mg of HER2 nanobody and 4.0 mg of Taq nanobody were successfully purified from 1 L of E. coli culture. The purified nanobodies exhibited proper folding, confirmed through circular dichroism and one-dimensional 1H NMR spectroscopy, and retained their functionality in target-specific immunoassays. These results demonstrate a promising strategy for the high-yield, soluble, and functional expression of challenging nanobodies in E. coli.Keywords: Protein expression, Nanobodies, Spy chaperone, Soluble expression Introduction The field of recombinant antibody engineering has grown significantly over the past twenty years, mainly due to the clinical success of antibody-based therapies [1]. Nanobodies, also called variable domain of heavy chain only antibody (VHHs), are the antigen-binding parts of heavy chain only antibodies naturally present in camelids, including camels and llamas [2]. They are small proteins, typically 12–15 kDa, that bind targets with high affinity and specificity [3]. Their single-domain structure is generally stable, can refold after denaturation, and tolerates genetic fusion [2,4], which supports recombinant production in bacteria or yeast and enables multivalent, bispecific, or enzyme-linked formats. Consequently, nanobodies have been widely used as targeting modules for therapies, diagnostics, research tools, and biosensing platforms [5]. However, the main challenge is often not affinity but the availability of sufficient soluble, functional nanobodies, because expression in Escherichia coli (E. coli) frequently results in aggregation into inclusion bodies and difficulties forming the correct disulfide bonds required for proper folding [6]. Nanobodies (VHHs) possess a conserved immunoglobulin fold stabilized by a canonical intradomain disulfide bond connecting cysteine residues in framework region 1 (FR1) and framework region 3 (FR3) (Cys22-Cys92, Kabat numbering). This disulfide bridge links the two β-sheets of the immunoglobulin fold and is essential for structural integrity [7]. Additionally, many nanobodies contain a non-canonical second disulfide bond, which varies by species and sequence: in camels, this is frequently found between the Complementarity-Determining Region 1 (CDR1) and Complementarity-Determining Region 3 (CDR3). This additional disulfide restricts the conformation of the extended CDR3 loop and enhances thermal stability without necessarily affecting antigen binding [7,8]. Recombinant protein expression is a foundational approach in molecular biology that enables the production of defined proteins for biochemical assays, structural studies, and biotechnological applications [9,10]. The Gram-negative bacterium E. coli is among the most widely used hosts for recombinant protein production because it grows rapidly, is inexpensive to culture, and is readily manipulated genetically [11,12]. Despite these advantages, high-level expression of recombinant proteins, including nanobodies, frequently overwhelms cellular folding and quality-control capacity, resulting in misfolding, proteolysis, and aggregation into inclusion bodies [13,14]. Recovery of active protein from inclusion bodies often requires solubilization and refolding steps, which can reduce yield and increase downstream processing complexity [14,15]. In addition, many nanobodies require one or more disulfide bonds for native stability and function, but the reducing environment of the E. coli cytoplasm can limit correct disulfide formation, further contributing to misfolding and loss of activity [[16], [17], [18]]. EcSpy (Spheroplast Protein Y from E. coli) is a small, stress-responsive chaperone found in the periplasm of E. coli, activated under envelope stress conditions and functioning without adenosine triphosphate (ATP). It can promote productive folding, inhibit aggregation, and bind a variety of non-native client proteins [19,20]. Mechanistic research has confirmed that EcSpy does not merely sequester unfolded clients. Moreover, it also allows client proteins to explore conformations and fold while remaining associated with the chaperone, blurring the classical distinction between holdases and foldases [20,21]. Thus, fusion of EcSpy with a nanobody could potentially aid its folding in two aspects: 1. Secretion of the EcSpy fused protein into the E. coli periplasm helps the formation of correct disulfide bonds in the nanobody; 2. The Binding of EcSpy with the exposed hydrophobic regions in unfolded or partially folded nanobodies keeps them from agglomeration long enough to complete correct folding [22]. As EcSpy forms an anti-parallel dimer, we constructed a tandem EcSpy fusion vector to improve the solubility and correct folding of two challenging nanobodies: one targeting HER2, a clinically important breast cancer biomarker, and another targeting Taq DNA polymerase, a common enzyme used in hot start polymerase chain reaction (PCR) workflows [[23], [24], [25], [26]]. This strategy increased the yield of correctly folded nanobodies. Circular dichroism (CD), one-dimensional 1H NMR, and enzyme-linked immunosorbent assay (ELISA) confirmed proper folding and retained functionality. Our results suggest that tandem EcSpy represents a promising fusion strategy for high-yield, soluble, and functional nanobody production in E. coli. Materials and methods Plasmid construction To establish a baseline for conventional expression strategies, a Small Ubiquitin-like Modifier (SUMO)-tagged construct was initially generated by cloning the Taq or HER2 nanobody sequence into a modified pET21a vector. This construct encodes an N-terminal decahistidine (His10) tag followed by a yeast SUMO domain and the nanobody of interest. To overcome the severe inclusion body formation observed with standard approaches, an optimized EcSpy-based construct was engineered using the pET-28a (+) backbone. EcSpy is an exogenous periplasmic molecular chaperone in E. coli that carries a N-terminal signal peptide (MRKLTALFVASTLALGAANLAHA) directing secretion into the oxidizing periplasmic compartment. The signal peptide is followed by a decahistidine tag His10 affinity tag, a tandem EcSpy module connected by a flexible peptide linker (GGGGSGGGGS) to maintain spatial flexibility and functional independence of the two chaperone units, and a TEV protease cleavage site (ENLYFQG) positioned immediately upstream of the nanobody to facilitate recovery of the native, tag-free nanobody after purification. The amino acid sequence of the HER2 nanobody was obtained from the Protein Data Bank (PDB ID: 5MY6), while the Taq nanobody sequence was identified and selected from a nanobody library constructed in our laboratory. All gene sequences were codon-optimized for expression in E. coli, synthesized commercially (GenScript Biotech Corporation), and cloned into their respective vectors. Protein expression and purification Recombinant plasmids were transformed into E. coli T7 Express (New England Biolabs, NEB) for protein expression. A single transformed colony was picked to inoculate into 5 mL of LB (Luria-Bertani) medium (10.0 g/L tryptone, 5.0 g/L yeast extract, 10.0 g/L NaCl) supplemented with 100 μg/mL kanamycin. This preculture was incubated overnight at 37°C with shaking at 200 rpm. The overnight culture was diluted 1:100 (v/v) into 100 mL of TB (Terrific Broth) medium (11.8 g/L tryptone, 23.6 g/L yeast extract, 9.4 g/L K2HPO4, 2.2 g/L KH2PO4) containing kanamycin (100 μg/mL). Cells were grown at 37°C with shaking at 220 rpm to mid-log phase (OD600 ≈ 0.5–0.6). This culture was then used to inoculate 900 mL of fresh TB-Kana medium, and incubation was continued under the same conditions until the culture reached the stationary phase (OD600 ≈ 1.5–2.0). Protein expression was induced by the addition of isopropyl β-d-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM. Cultures were transferred to 18°C and incubated with shaking for 18 h. Post-induction, cells were harvested by centrifugation at 6000×g for 30 min at 4°C. The cell pellet was resuspended in 150 mL of alkaline lysis buffer (50 mM NaHCO3, 300 mM NaCl, pH 11.0), supplemented with 0.1 mM phenylmethylsulphonyl fluoride (PMSF) and 0.01 mg/mL Deoxyribonuclease I. Cell lysis was performed using a high-pressure homogenizer. The lysate was clarified by centrifugation at 20,000×g for 45 min at 4°C. The soluble protein fraction was applied to a Ni–nitrilotriacetic acid (Ni-NTA) affinity column (Qiagen) pre-equilibrated with lysis buffer (without protease/nuclease inhibitors). The column was washed with 200 mL of wash buffer, and the sample was applied in three sequential steps with increasing imidazole concentrations (10 mM, 20 mM, and 30 mM imidazole in lysis buffer). The His-tagged target protein was subsequently eluted using 50 mL of elution buffer A (50 mM NaHCO3, 300 mM NaCl, 500 mM imidazole, pH 11.0). TEV protease cleavage and final purification Before tandem EcSpy fusion cleavage, the eluted protein was dialysed overnight against the Tobacco Etch Virus (TEV) digestion buffer (25 mM Tris-HCl, 150 mM NaCl, 0.1 mM Dithiothreitol (DTT), pH 8.0) at 4°C. The dialysate was clarified by centrifugation at 12,000×g for 20 min at 4 °C.TEV protease was added to the supernatant at a 40:1 (target protein: enzyme) mass ratio, and the cleavage reaction was incubated overnight at 4°C. Following digestion, the sample was dialyzed back into buffer A (50 mM NaHCO3, 300 mM NaCl, pH 11.0) to precipitate contaminants. The precipitate was removed by centrifugation at 20,000×g for 20 min at 4°C, and the supernatant was retained. Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis (SDS-PAGE) was used to analyze both the precipitate and supernatant fractions to monitor cleavage efficiency. For constructs with an N-terminal His-tag, the cleaved sample was applied to a reverse Ni-NTA affinity column pre-equilibrated with buffer A. The flow-through fraction, containing the Taq and HER2 nanobody, was collected. A final polishing step was performed by size-exclusion chromatography (SEC) using a HiLoad™ Superdex™ 75 prep grade column (Cytiva, formerly GE Bioscience) equilibrated with SEC buffer (20 mM Sodium phosphate, 150 mM NaCl, pH 7.4). Fractions corresponding to the major peak observed by size exclusion chromatography were pooled, concentrated using an appropriate centrifugal filter, and stored at −20°C for subsequent applications. CD spectroscopy The secondary structures of the purified nanobodies were analyzed by CD spectroscopy. Measurements were performed on a Chirascan spectropolarimeter (Applied Photophysics Ltd.). The protein samples were diluted to a final concentration of 74 μg/mL in 10 mM sodium phosphate buffer (pH 7.0). Spectra were recorded at room temperature in a quartz cuvette with a 1 mm path length over a wavelength range of 190–260 nm. Three consecutive scans were acquired for each sample and averaged to improve the signal-to-noise ratio. Baseline correction was performed by subtracting the buffer-only spectrum, recorded under identical conditions. 1H NMR spectroscopy One-dimensional 1H nuclear magnetic resonance (1H NMR) spectra were acquired at 298 K on a 600 MHz Bruker Avance spectrometer equipped with a cryogenic probe. Samples were prepared in NMR buffer (20 mM sodium phosphate, 50 mM NaCl, 10% D2O, pH 7.4) at concentrations of 0.2 mM (HER2 nanobody) and 0.1 mM (Taq nanobody). Spectra were recorded using the zggpw5 pulse sequence with 512 scans and 4 dummy scans. Data were processed with Topspin 3.7 (Bruker Biospin). ELISA assay ELISA for HER2 nanobody Purified HER2 nanobody (2.0 μg/mL) was coated onto a 96-well microplate (100 μL/well) and incubated overnight at 4°C. The plate was washed five times with Phosphate-Buffered Saline with Tween-20 PBST (PBS, pH 7.4, containing 0.5% v/v Tween-20). Non-specific binding sites were blocked with 200 μL/well of 5% (w/v) non-fat dry milk in PBST for 2 h at 37°C. After discarding the blocking solution and drying the plate, wells were washed five times with PBST. Serial dilutions of HER2 antigen (Sangon Biotech, D111419-0100) were added and incubated for 1 h at 37°C. Wells coated with bovine serum albumin (BSA, 2.0 μg/mL) under identical conditions served as negative controls. Following five washes, 100 μL of horseradish peroxidase (HRP)-conjugated rabbit anti camelid VHH antibody (GenScript, A01861-200; diluted 1:5000) was added to each well. The plate was sealed and incubated at 37°C for 60 min. After a final wash step, 100 μL of freshly prepared 3,3′,5,5′-tetramethylbenzidine (TMB) substrate solution (containing 9.8 mL citric acid, 30 μL 30% H2O2, and 200 μL TMB stock 130 mg/50 mL) was added per well and incubated for 15 min at 37°C. The reaction was terminated with 2 M H2SO4, and absorbance was measured at 450 nm. ELISA for Taq nanobody Recombinant Taq polymerase (5.0 μg/mL) was adsorbed onto a 96-well microplate (100 μL/well) and incubated overnight at 4°C. Wells coated with BSA (5.0 μg/mL) under identical conditions served as negative controls. The plate was washed five times with PBST and blocked with 200 μL/well of 5% (w/v) non-fat dry milk in PBST for 2 h at 37°C. After washing five times with PBST, serially diluted Taq nanobody (100 μL/well) was added and incubated for 1 h at 37°C. Following five washes, 100 μL of HRP-conjugated rabbit anti camelid VHH antibody (GenScript, A01861-200; 1:5000 dilution) was added per well and incubated at 37°C for 60 min. After a final wash, 100 μL of TMB substrate solution was added per well and incubated for 15 min at 37°C. The reaction was stopped with 2 M H2SO4, and absorbance was read at 450 nm. Results Single-domain antibodies (VHHs) consist of a single variable domain containing conserved four FRs and CDRs responsible for antigen binding. The structural organization of a typical VHH nanobody, including the conserved disulfide bond that contributes to domain stability [27,28], is illustrated in Fig. 1. Schematic diagram of a VHH nanobody showing framework regions, complementarity-determining loops, and conserved disulfide bonds. In Fig. 1 nanobodies typically possess two conserved disulfide bonds: the canonical disulfide bridge between FR1 and FR3 (highlighted by red arrows), which stabilizes the characteristic immunoglobulin (Ig) fold; and an additional disulfide bond, frequently formed between the CDR1 and CDR3 loops, which restricts and maintains the architecture of the antigen-binding site. The correct formation of these disulfide bonds within the oxidative periplasmic space is critical for folding efficiency and structural integrity. Initial fusion strategies yield insoluble nanobody expression Initial attempts to express HER2 and Taq nanobodies in E. coli using N-terminal SUMO fusion tags resulted predominantly in insoluble protein. SDS–PAGE analysis of soluble and insoluble fractions showed that the majority of the expressed SUMO–HER2 and SUMO–Taq nanobodies were present in the pellet fraction (Supplementary Fig. S1A and S1B). This distribution is consistent with the formation of inclusion bodies, likely resulting from the reducing environment of the E. coli cytoplasm, which impairs disulfide bond formation in the nanobodies. Tandem EcSpy fusion dramatically enhances soluble expression Fusion with tandem EcSpy resulted in a pronounced shift of both HER2 and Taq nanobodies from the insoluble to the soluble fraction (Fig. 2B and C), representing a substantial improvement compared with SUMO-based expression (Fig. S1). To further improve folding and solubility, a secretion-based expression strategy was adopted. Tandem EcSpy was fused to its native signal peptide to direct the fusion protein to the periplasmic space. The periplasmic environment of E. coli provides oxidative conditions that promote disulfide bond formation, which is important for the stability of antibody fragments. To verify subcellular localization, periplasmic extraction was performed using the cold osmotic shock method. The detailed protocol for periplasmic extraction is provided in the Supplementary Material Methods. SDS–PAGE analysis showed that the tandem EcSpy–VHHs fusion protein was predominantly detected in the periplasmic fraction, with minimal signal in the protoplast fraction (Fig. S2). These results indicate that the native EcSpy signal peptide successfully directed the fusion protein into the periplasmic space. Fusion of nanobodies with an N-terminal signal peptide and tandem EcSpy significantly enhances soluble expression. (A) A Spy-Spy tandem dimer tag was constructed by genetic fusion of two Spy sequences connected by a GGGGSGGGGS linker. (B–C) SDS-PAGE analysis of soluble (S) and insoluble (P) fractions from whole-cell E. coli lysates and subsequent Ni-NTA purification of nanobodies carrying a tandem EcSpy (B: HER2 nanobody; C: Taq nanobody). Arrows indicate target Spy-tagged proteins (∼50 kDa): M, protein marker; F, flow-through; W, wash; E, elution fraction. Notably, proteins fused to tandem EcSpy also exhibited improved behavior during immobilized metal affinity chromatography (IMAC), binding efficiently to the Ni–NTA resin and eluting as sharper, more concentrated peaks. Based on these observations, the signal peptide–EcSpy fusion strategy enabled efficient soluble expression of otherwise difficult-to-express nanobodies in the bacterial periplasm. Nanobodies maintain solubility following tandem EcSpy cleavage Following affinity purification of the soluble tandem EcSpy nanobody fusions, the fusion partner was cleaved to recover the native nanobody. Protease cleavage was carried out by incubating the purified fusions with TEV protease overnight at 4°C in the cleavage buffer. The reaction proceeded to near-completion, as assessed by SDS-PAGE, with no observable precipitation during or after digestion (Fig. 3B and C). The dialyzed sample was then passed over a Ni-NTA column, where the His10-tagged tandem EcSpy moiety was retained, while the untagged nanobodies were collected in the flow-through. SDS-PAGE analysis confirmed efficient separation and recovery of the nanobodies (Fig. 3B and C). Critically, the nanobody remained soluble throughout the cleavage and purification processes. No precipitation was observed following tag removal, indicating that the tandem EcSpy fusion strategy successfully maintained nanobody solubility even after the chaperone domain was cleaved. A doublet observed at approximately 35 kDa corresponds to the cleaved His-Spy-Spy fusion and likely results from minor proteolytic degradation at the flexible linker region; importantly, the target nanobody remained intact and soluble, suitable for downstream structural and functional studies. This partial linker degradation occurring on the tandem EcSpy tag does not impair purification efficiency and the final nanobody purity. Following cleavage of the EcSpy, the target protein retains solubility. (A) Schematic of the cleavable EcSpy construct, featuring a TEV protease recognition site (ENLYFQG) inserted between the EcSpy and the target nanobodies. (B–C) SDS-PAGE analysis of Ni-NTA affinity chromatography fractions after TEV protease digestion for HER2 nanobody (B) and Taq nanobody (C). Lanes: M, protein marker; A, the digested sample prior to reverse Ni-NTA application); F, flow-through; W, wash; E, imidazole elution. Final purification by size-exclusion chromatography (SEC) (Superdex 75) yielded a homogeneous product. The nanobodies eluted as a single, symmetrical peak corresponding to an apparent molecular weight consistent with a monomeric nanobody, and SDS-PAGE of the peak fraction confirmed high purity (Fig. 4A and B). This indicates that the solubility and homogeneous size distribution conferred by the Spy secretion system were retained after tandem EcSpy chaperone removal. Nanobodies were purified to high homogeneity by size-exclusion chromatography (SEC). (A) SEC elution profile and corresponding SDS-PAGE analysis of purified HER2 nanobody. (B) SEC elution profile and corresponding SDS-PAGE analysis of purified Taq nanobody. Purification was performed using a Superdex-75 column (GE Bioscience) equilibrated with SEC buffer A (20 mM sodium phosphate, 150 mM NaCl, pH 7.4). The nanobody eluted at approximately 90 mL Because imidazole in the intermediate elution fractions interferes with standard colorimetric protein assays, the protein amounts and recovery rates for these steps were estimated semi-quantitatively. Specifically, direct spectrophotometric quantification was not applicable to imidazole-containing fractions due to significant interference at 280 nm; therefore, relative band intensities from SDS-PAGE were used as a proxy for protein amounts in these intermediate steps, while absolute yield was anchored to the final A280 measurement of the purified nanobody after SEC. Densitometric analysis of the SDS-PAGE gels was performed using ImageJ software to determine the relative band intensities (area integrals). These ratios, combined with the precise protein concentration of the final tag-free nanobody, ultimately determined using Nanodrop (determined by A280 after SEC), were used to calculate the yield and recovery for the previous purification steps (Table 1). Following a comprehensive multi-step purification procedure comprising initial Ni-NTA affinity chromatography, fusion tag removal via TEV protease cleavage, reverse Ni-NTA chromatography, and a final polishing step using Superdex 75 size-exclusion chromatography, 1 L of E. coli culture ultimately yielded approximately 10.0 mg of HER2 nanobody and 4.0 mg of Taq nanobody. Table 1Purification summary of the recombinant Tandem EcSpy nanobody from 1 L of E. coli culture.Table 1Purification Step (HER2 nanobody)Volume/(mL)Concentration/(mg/mL)Total Protein/(mg)Yield/(mg/L)1. Clarified cell lysate150N/DN/DN/D2. Ni-NTA chromatography (Tandem EcSpy-nanobody)1250.675.075.03. TEV cleavage & Reverse Ni-NTA500.315.015.04. Size-exclusion chromatography200.510.010.0Purification Step (Taq nanobody)Volume/(mL)Concentration/(mg/mL)Total Protein/(mg)Yield/(mg/L)1. Clarified cell lysate150N/DN/DN/D2. Ni-NTA chromatography (Tandem EcSpy-nanobody)1000.2727.027.03. TEV cleavage & Reverse Ni-NTA250.328.08.04. Size-exclusion chromatography200.204.04.0(N/D = Not determined). Purification summary of the recombinant Tandem EcSpy nanobody from 1 L of E. coli culture. (N/D = Not determined). Structural analyses confirm the correctly folded conformation of purified nanobodies Nanobodies depend on a compact immunoglobulin fold stabilized by intradomain disulfide bonding. We confirmed that the purified nanobodies maintained the expected native conformation using a combination of structural and functional assays. The CD spectra of the purified nanobodies displayed a characteristic negative minimum near 218 nm and a positive band near 195 nm, consistent with a predominant β-sheet secondary structure typical of the immunoglobulin variable domain fold (Fig. 5A and B). Secondary structure content was estimated by spectral deconvolution using the BeStSel web server [29]. Analysis of the Taq nanobody spectrum yielded an estimated β-strand content of 40% and α-helical content of 11%, consistent with the immunoglobulin-like fold reported for VHH domains. Spectroscopic analysis of the HER2 nanobody showed a similar β-sheet-dominated characteristic exceeding 30%, further confirming the correct folding of both purified proteins. These spectral features are characteristic of a β-sheet-dominated immunoglobulin variable domain fold, consistent with the secondary structure expected for correctly folded VHH domains. One-dimensional 1H NMR spectroscopy was used to assess the overall folding quality of the purified nanobodies. The 1H NMR spectra of the purified nanobodies displayed excellent amide proton signal dispersion in the downfield region (8.5–10.5 ppm), with numerous sharp, well-resolved resonance peaks [30,31] (Fig. 5C and D). This spectral signature is characteristic of a stably folded protein with a unique tertiary structure. In contrast to unfolded or heavily aggregated proteins, which typically exhibit limited chemical shift dispersion and broad, poorly resolved signals, the purified nanobodies produced spectra with clear dispersion across the amide and aliphatic regions and with well-resolved resonances. The upfield signals in the 1H NMR spectra also demonstrate the folding behavior of the protein. These features are indicative of the absence of aggregation or misfolding. Such dispersion patterns have been documented explicitly for properly folded nanobodies [30], confirming the structural properties of our recombinant nanobodies. The functional integrity of the purified nanobodies was validated using (ELISA) (Fig. 5E and F) [32]. For the anti-HER2 nanobody, a sandwich ELISA was employed: purified HER2 nanobody was immobilized as the capture reagent, serially diluted recombinant HER2 antigen was subsequently applied, and bound antigen was detected with an HRP-conjugated anti-VHH secondary antibody. For the anti-Taq polymerase nanobody, a direct ELISA format was used, in which recombinant Taq polymerase was adsorbed directly to the plate and serially diluted Taq nanobody was added as the detecting reagent, followed by the same HRP-conjugated secondary antibody. Structural integrity and antigen-binding activity of purified nanobodies. (A, B) Far UV circular dichroism (CD) spectra (190–260 nm) of HER2 nanobody (A) and Taq nanobody (B), indicating well-folded secondary structure. (C, D) One-dimensional 1H NMR spectra in the aromatic region (8.5–10.5 ppm upper panel) and upfield methyl proton region (Lower panel) for HER2 nanobody (C) and Taq nanobody (D), showing well-dispersed resonances consistent with a properly folded protein. (E, F) ELISA binding curves of HER2 nanobody to immobilized HER2 (E) and Taq nanobody to immobilized Taq (F), plotted as OD 450 nm versus antigen concentration; the negative control showed a background signal. As shown in Fig. 5E and F, both HER2 nanobody and Taq nanobody, exhibited potent, dose-dependent binding to their respective antigens, with signal saturation observed at higher concentrations. The binding was specific, as no significant signal was detected in wells coated with BSA as a negative control. Together, these data confirm that the nanobodies purified under our optimized conditions retain their native, high-affinity antigen-binding function. Collectively, the CD, NMR, and ELISA data provide consistent evidence that our secretion-based expression and purification strategy yields nanobodies in a correctly folded, native like conformation. These results demonstrate that the final products are not soluble aggregates or disordered random coils, but rather monodisperse, structurally defined proteins suitable for functional and structural studies. Discussion Efficient production of soluble nanobodies in E. coli remains a common bottleneck in recombinant antibody engineering. Although nanobodies possess a relatively stable immunoglobulin fold, many VHH domains still aggregate during bacterial expression, particularly when correct disulfide bond formation and folding cannot keep pace with rapid protein synthesis [33]. As a result, aggregation-prone nanobodies frequently accumulate as inclusion bodies, limiting their functional yield [34]. In this study, we addressed this challenge by designing a tandem EcSpy fusion strategy that combines periplasmic targeting with chaperone-assisted folding. In this tandem structure, the flexible C-terminus of one Spy monomer is linked to the flexible N-terminus of another monomer via a short glycine-serine linker. The native signal peptide of EcSpy directs the fusion protein to the periplasm, an oxidizing environment that facilitates disulfide bond formation, which is critical for the structural stability of nanobodies [35,36]. At the same time, Spy functions as an ATP-independent chaperone capable of stabilizing partially folded intermediates and preventing off-pathway aggregation [37,38]. This dual mechanism likely promotes productive folding of nanobodies during and after translocation. Consistent with this mechanism, the tandem EcSpy system significantly increased the soluble expression of two aggregation-prone nanobodies, HER2 and Taq. Importantly, the nanobodies remained soluble after TEV protease removal of the EcSpy tag, with no precipitation observed throughout the cleavage and subsequent purification steps. This behavior suggests that EcSpy promotes genuine productive folding of the client nanobody, rather than acting merely as a physical solubility shield that masks aggregation-prone surfaces. Structural characterization by CD and 1H NMR spectroscopy, together with antigen-binding assays, further confirmed that the purified nanobodies retained their native structure and functionality. These results demonstrate that tandem EcSpy fusion provides an effective strategy for improving the soluble expression of challenging nanobodies in E. coli, offering a simple approach that would be extendable to other challenging nanobody targets. Our tandem EcSpy strategy presents notable advantages over existing expression platforms. While conventional N-terminal fusion tags, such as SUMO, are widely utilized to enhance the apparent solubility of recombinant proteins, they often lack the intrinsic capacity to assist in the complex folding pathways required by disulfide-rich targets [39]. Consequently, expressing complex proteins like nanobodies with SUMO tags in the reducing cytoplasm of E. coli frequently fails to prevent misfolding, ultimately resulting in the accumulation of inactive inclusion bodies [40]. In contrast, our fusion strategy overcomes these fundamental limitations by coupling active chaperone-mediated folding with signal peptide-directed translocation to the oxidative periplasm, thereby ensuring both high solubility and the correct formation of canonical disulfide bonds. Furthermore, because the wild-type Spy chaperone naturally forms active dimers, our engineered tandem arrangement likely stabilizes this functional conformation, providing an expanded interaction surface to efficiently accommodate the folding intermediates of the nanobodies. The generalizability of the tandem EcSpy strategy should be tested on a broader panel of nanobodies with varying biophysical properties, including different CDR compositions, disulfide bond numbers, and aggregation propensities. Conclusion In this study, we developed a tandem EcSpy fusion strategy to improve the soluble expression of aggregation-prone nanobodies in E. coli. By combining periplasmic targeting with the chaperone activity of Spy, this system promotes productive folding and suppresses aggregation during expression. Using two challenging nanobodies, which failed to be soluble when expressed with a SUMO tag, we demonstrated that the EcSpy tag significantly enhances their soluble yield. After removal of the EcSpy tag, both nanobodies remained soluble, correctly folded, and functionally active. Overall, this work provides a simple, effective and promising strategy for producing functional nanobodies in E. coli and may facilitate the expression of other aggregation-prone antibody fragments. CRediT authorship contribution statement Xingyu Wang: Writing – original draft, review & editing Visualization, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Ali Raza: Writing – original draft, review & editing Visualization, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Zhiqing Tao: Methodology. Guan Wang: Investigation. Xu Zhang: Resources, Funding acquisition, Conceptualization. Maili Liu: Resources, Funding acquisition, Conceptualization. Lichun He: Writing – original draft, review & editing Visualization, Supervision, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. Data availability Data will be made available on request. Declaration of competing interest The authors declare the following financial interests/personal relationships, which may be considered as potential competing interests: Maili Liu and Lichun He are editorial board members of Magnetic Resonance Letters, but were not involved in the editorial review or the decision to publish this article. Acknowledgement This work has received funding from National Natural Science Foundation of China grants 22574164, the Strategic Priority Research Program of the Chinese Academy of Sciences XDB0540000, and XDB1300000. Biographies Xingyu Wang received a bachelor's degree in applied chemistry from Wuhan Institute of Technology in 2023. He is currently pursuing a master's degree at the University of Chinese Academy of Sciences, jointly affiliated with the Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences, China. Ali Raza received a Bachelor's degree in Organic Chemistry in 2019 from the Government College University, Faisalabad, Pakistan. He received his Master's degree in Chemistry in 2023 from the University of Agriculture, Faisalabad, Pakistan. Currently, he is pursuing a doctor's degree in Analytical chemistry at the University of Chinese Academy of Sciences, jointly affiliated with the Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences, China. His research interests focused on the mechanism of Biological Molecules Explored via NMR spectroscopy in Solution and their native environments. Lichun He was awarded a Ph.D. fellowship from the Helmholtz Center for Infection Research in 2010 and received his doctorate degree in 2014. Afterward, he worked together with Prof. Sebastian Hiller at the University of Basel, Biozentrum, to investigate chaperone mechanisms. In 2019, he joined the Innovation Academy for Precision Measurement Science and Technology, CAS, China, with research interests in studies of biomolecular NMR spectroscopy. Footnotes Peer review under the responsibility of Innovation Academy for Precision Measurement Science and Technology (APM), CAS. Supplementary data to this article can be found online at https://doi.org/10.1016/j.mrl.2026.200287. Supplementary data The following is the Supplementary data to this article. Multimedia component 1 References Associated Data Supplementary Materials Multimedia component 1 Data Availability Statement Data will be made available on request.